RT Journal Article
SR Electronic
T1 Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e235816
DO 10.1136/bcr-2020-235816
VO 13
IS 9
A1 Kristo Marvyin
A1 Eirik Brekka Tjønnfjord
A1 Unni Mathilde Breland
A1 Geir Erland Tjønnfjord
YR 2020
UL http://casereports.bmj.com/content/13/9/e235816.abstract
AB Chronic lymphatic leukaemia (CLL) is the most common leukaemia in the Western world. Ibrutinib, a tyrosine kinase inhibitor, is the treatment of choice on relapse or p53-dysfunction. Richter’s transformation to diffuse large B cell lymphoma is most often seen. However, transformation to other aggressive lymphomas as plasmablastic lymphoma (PBL) does occur. PBL is an extremely aggressive lymphoma and is usually treated using a CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine and prednisone/dexamethasone), but with poor outcome. The only curative treatment is allogeneic stem cell transplant (ASCT).We report on a case of CLL treated with ibrutinib that underwent transformation to PBL. Due to high expression of CD138, we added daratumumab to the chemotherapy with a good, but transitory response. The case did not make it to an ASCT. Targeting CD138 by daratumumab may be added to chemoimmune therapy for PBL.